CBS Test Buys of Unapproved Retatrutide: Brooklyn Bodega Vial Had No Peptide, Bacteria

4.0 · 10d ago · US

The Facts

  • CBS News correspondent Adam Yamaguchi bought 20 mg of retatrutide, an experimental peptide drug Eli Lilly is studying for obesity, from Reset Wellness's website; it arrived a week later with no consultation with a health professional. CBS News only
  • Yamaguchi also bought retatrutide from the website of Bodystreet Jupiter, a Florida gym, after confirming he met a BMI requirement; it arrived two days later without a consultation. CBS News only
  • Yamaguchi bought a vial labeled 'Retatrutide' for $90 at a Brooklyn bodega; the label read 'Research use only, not for human consumption.' CBS News only
  • University of Iowa research scientist Jason Galpin found both online samples consistent with a basic standard he created for retatrutide, which is not the same as the drug in Eli Lilly's clinical trials. CBS News only
  • Galpin found the bodega sample did not appear to contain a peptide; it contained phenylacetic acid, a filler commonly found in fragrances and lip balms. CBS News only
Dive deeper · 4 more factsShow less
  • Testing by Carl Ross of the University of Iowa's Center for Biocatalysis and Bioprocessing found 13 bacterial colonies in the bodega sample. CBS News only
  • Retatrutide is not FDA approved and remains in clinical trials. CBS News only
  • Eli Lilly said in a statement that a single test is a snapshot and does not guarantee safety, and called on the FDA and DOJ to act against the black market. It cited prior CBS reporting of two deaths associated with black-market retatrutide and a Bloomberg report on contamination at two former FDA Green List manufacturers. CBS News only
  • CBS News said INDR Labs, Reset and Bodystreet had not responded to requests for comment. CBS News only

Context

CBS News bought products labeled as retatrutide from two online sellers and a Brooklyn bodega and had them analyzed at the University of Iowa. The online samples met a basic internal standard, while the bodega sample contained no peptide and showed bacterial contamination.

Yale physician Reshma Ramachandran told CBS that buyers of such products are effectively acting as test subjects because the drug has not been shown safe and effective. Eli Lilly said limited testing of single samples does not make illicit products safe.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 1.

5 Informed Citizen This investigative test-buy reveals a contaminated black-market vial and unregulated online sales of an unapproved drug, a moderately important consumer-safety finding, but it is a single-outlet report without a regulatory action or broad immediate impact on ordinary people.
4 Science & Tech Analyst This is a journalistic test-buy investigation revealing contaminated black-market retatrutide in one bodega sample, with limited scope (single samples) and no new regulatory action, so its impact is niche to moderate rather than broad.
4 News Editor This investigative test-buy reveals a concrete finding of contaminated, mislabeled black-market product at a Brooklyn bodega, but it affects a limited number of buyers and is a single-sample report rather than a major event with widespread immediate impact.
4 Global Affairs Analyst The story reports an investigative test-buy finding that a bodega vial of unapproved retatrutide contained no peptide and bacteria, a concrete but localized consumer-safety finding with limited immediate geopolitical or broad impact, while Eli Lilly's statements are rhetoric without new action.
4 Critical Reader This is an investigative test-buy reporting contamination and mislabeling of unapproved retatrutide sold via online sellers and a bodega, a limited-scope finding with no regulatory action or measured population impact yet, though it touches a public-health concern.
4 Policy Expert This is an investigative journalism test-buy revealing contaminated and mislabeled unapproved drug products in a local bodega, a concrete finding with limited direct impact, though it raises public safety concerns and may prompt regulatory action.
4 Business Analyst This is a media investigation revealing contaminated unapproved black-market peptide samples, a notable public health concern with limited market impact, and Eli Lilly's statement and calls for enforcement are rhetoric without a concrete regulatory action.

Source

← All stories